Literature DB >> 23551634

Visceral varicella zoster virus infection after allogeneic stem cell transplantation.

N Doki1, S Miyawaki, M Tanaka, D Kudo, A Wake, K Oshima, H Fujita, T Uehara, R Hyo, T Mori, S Takahashi, S Okamoto, H Sakamaki.   

Abstract

INTRODUCTION: Varicella zoster virus (VZV) disease is one of the major infectious complications that can occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Many reports have shown visceral VZV infection, a special type of VZV disease, to be rare. However, few studies so far have included a large number of patients.
FINDINGS: Visceral VZV infection was found in 20 (0.8%) of 2411 patients who underwent allo-HSCT at our hospitals. Seventeen (85%) patients were taking immunosuppressive agents at the time of presentation with zoster. The presenting symptom was abdominal pain in 16 patients (80%), unconsciousness in 3 patients (15%), and no symptoms in 1 patient. The mean time interval from allo-HSCT to symptomatic visceral VZV infection was 273 days (103-800 days). The eruptions appeared within 3 days (0-13) after the first symptoms. Treatment with intravenous acyclovir was initiated before the appearance of eruptions in 3 of 18 patients (all 3 survived) with vesicular eruptions, the same day in 12 patients (11 survived, 1 died), and after the appearance in 3 patients (1 survived, 2 died). The overall mortality was 20%.
CONCLUSION: In conclusion, these data confirm that the incidence of visceral VZV infection is infrequent, but this disease is serious. When patients being treated with immunosuppressive agents demonstrate abdominal pain or unconsciousness, the possibility of visceral VZV infection should be considered as well as earlier therapeutic intervention.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23551634     DOI: 10.1111/tid.12073

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  6 in total

1.  Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination.

Authors:  Kareem Jamani; Judy MacDonald; Martin Lavoie; Tyler S Williamson; Christopher B Brown; Ahsan Chaudhry; Victor H Jimenez-Zepeda; Peter Duggan; Jason Tay; Douglas Stewart; Andrew Daly; Jan Storek
Journal:  Blood Adv       Date:  2016-11-30

2.  Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis-possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report.

Authors:  Masato Habuka; Yoko Wada; Yoichi Kurosawa; Suguru Yamamoto; Yusuke Tani; Riuko Ohashi; Yoichi Ajioka; Masaaki Nakano; Ichiei Narita
Journal:  BMC Res Notes       Date:  2018-03-05

Review 3.  Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Authors:  Liang-Kung Chen; Hidenori Arai; Liang-Yu Chen; Ming-Yueh Chou; Samsuridjal Djauzi; Birong Dong; Taro Kojima; Ki Tae Kwon; Hoe Nam Leong; Edward M F Leung; Chih-Kuang Liang; Xiaohong Liu; Dilip Mathai; Jiun Yit Pan; Li-Ning Peng; Eduardo Rommel S Poblete; Philip J H Poi; Stewart Reid; Terapong Tantawichien; Chang Won Won
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090

4.  Visceral Varicella-Zoster Virus Infection Presenting with Severe Abdominal Pain without a Rash in a Patient with Psoriatic Arthritis Treated with Infliximab Biosimilar and Steroids: A Case Report.

Authors:  Nikolaos Spernovasilis; Maria Raissaki; Ioanna Papakitsou; Sofia Pitsigavdaki; Kypros Louka; Emmanouil Tavlas; Diamantis P Kofteridis
Journal:  Mediterr J Rheumatol       Date:  2021-06-25

5.  Visceral disseminated varicella zoster virus infection following COVID-19 vaccination in an allogeneic stem cell transplant recipient.

Authors:  Mitsutaka Nishimoto; Nobuhiro Sogabe; Masayuki Hino
Journal:  Transpl Infect Dis       Date:  2022-03-02

6.  Systemic lupus erythematosus with visceral varicella: A case report.

Authors:  Jing Zhao; Mei Tian
Journal:  World J Clin Cases       Date:  2022-09-06       Impact factor: 1.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.